Treatment options for early breast cancer in elderly women

Umberto Basso, Antonella Brunello, Claudia Pogliani, Silvio Monfardini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts on mortality of elderly women, especially if not adequately treated. As confirmed by meta-analyses, hormonal therapy is the most effective adjuvant measure for patients with localized disease, whereas the decrease in the benefit of cytotoxic treatment with increased risk of toxicity make the decision on when and how to administer it a major challenge for the medical oncologist. Careful evaluation of biological prognostic factors, performance status and geriatric parameters, such as functional independence, comorbidities and cognitive function of the patient, along with determination of her life expectancy and preferences, represent the relevant information on which the oncologist should ground their decision for integrated treatment with conservative surgery, radiotherapy and hormonochemotherapy in otherwise healthy women, or attenuated or palliative measures for the frail patients, in order to maximize the balance of benefits and toxicities. The aims of this review are to summarize the most relevant concepts for decision making in the clinical practice and discuss the results of recent research concerning the additional needs of elderly women with early breast cancer.

Original languageEnglish
Pages (from-to)197-211
Number of pages15
JournalExpert Review of Anticancer Therapy
Volume4
Issue number2
Publication statusPublished - Apr 2004

Fingerprint

Breast Neoplasms
Therapeutics
Biological Factors
Life Expectancy
Geriatrics
Cognition
Meta-Analysis
Comorbidity
Radiotherapy
Mortality
Research
Oncologists

Keywords

  • Adjuvant
  • Breast cancer
  • Chemotherapy
  • Elderly
  • Tamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Treatment options for early breast cancer in elderly women. / Basso, Umberto; Brunello, Antonella; Pogliani, Claudia; Monfardini, Silvio.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 2, 04.2004, p. 197-211.

Research output: Contribution to journalArticle

Basso, Umberto ; Brunello, Antonella ; Pogliani, Claudia ; Monfardini, Silvio. / Treatment options for early breast cancer in elderly women. In: Expert Review of Anticancer Therapy. 2004 ; Vol. 4, No. 2. pp. 197-211.
@article{9f74e08effa34df6baff5a8fc76eed0b,
title = "Treatment options for early breast cancer in elderly women",
abstract = "In clinical practice, approximately 50{\%} of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts on mortality of elderly women, especially if not adequately treated. As confirmed by meta-analyses, hormonal therapy is the most effective adjuvant measure for patients with localized disease, whereas the decrease in the benefit of cytotoxic treatment with increased risk of toxicity make the decision on when and how to administer it a major challenge for the medical oncologist. Careful evaluation of biological prognostic factors, performance status and geriatric parameters, such as functional independence, comorbidities and cognitive function of the patient, along with determination of her life expectancy and preferences, represent the relevant information on which the oncologist should ground their decision for integrated treatment with conservative surgery, radiotherapy and hormonochemotherapy in otherwise healthy women, or attenuated or palliative measures for the frail patients, in order to maximize the balance of benefits and toxicities. The aims of this review are to summarize the most relevant concepts for decision making in the clinical practice and discuss the results of recent research concerning the additional needs of elderly women with early breast cancer.",
keywords = "Adjuvant, Breast cancer, Chemotherapy, Elderly, Tamoxifen",
author = "Umberto Basso and Antonella Brunello and Claudia Pogliani and Silvio Monfardini",
year = "2004",
month = "4",
language = "English",
volume = "4",
pages = "197--211",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Treatment options for early breast cancer in elderly women

AU - Basso, Umberto

AU - Brunello, Antonella

AU - Pogliani, Claudia

AU - Monfardini, Silvio

PY - 2004/4

Y1 - 2004/4

N2 - In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts on mortality of elderly women, especially if not adequately treated. As confirmed by meta-analyses, hormonal therapy is the most effective adjuvant measure for patients with localized disease, whereas the decrease in the benefit of cytotoxic treatment with increased risk of toxicity make the decision on when and how to administer it a major challenge for the medical oncologist. Careful evaluation of biological prognostic factors, performance status and geriatric parameters, such as functional independence, comorbidities and cognitive function of the patient, along with determination of her life expectancy and preferences, represent the relevant information on which the oncologist should ground their decision for integrated treatment with conservative surgery, radiotherapy and hormonochemotherapy in otherwise healthy women, or attenuated or palliative measures for the frail patients, in order to maximize the balance of benefits and toxicities. The aims of this review are to summarize the most relevant concepts for decision making in the clinical practice and discuss the results of recent research concerning the additional needs of elderly women with early breast cancer.

AB - In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts on mortality of elderly women, especially if not adequately treated. As confirmed by meta-analyses, hormonal therapy is the most effective adjuvant measure for patients with localized disease, whereas the decrease in the benefit of cytotoxic treatment with increased risk of toxicity make the decision on when and how to administer it a major challenge for the medical oncologist. Careful evaluation of biological prognostic factors, performance status and geriatric parameters, such as functional independence, comorbidities and cognitive function of the patient, along with determination of her life expectancy and preferences, represent the relevant information on which the oncologist should ground their decision for integrated treatment with conservative surgery, radiotherapy and hormonochemotherapy in otherwise healthy women, or attenuated or palliative measures for the frail patients, in order to maximize the balance of benefits and toxicities. The aims of this review are to summarize the most relevant concepts for decision making in the clinical practice and discuss the results of recent research concerning the additional needs of elderly women with early breast cancer.

KW - Adjuvant

KW - Breast cancer

KW - Chemotherapy

KW - Elderly

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=1842790409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842790409&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 197

EP - 211

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -